These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21885526)

  • 41. Tocilizumab for Giant Cell Arteritis.
    Kwan CC; Thyparampil PJ
    Int Ophthalmol Clin; 2020; 60(2):57-62. PubMed ID: 32205653
    [No Abstract]   [Full Text] [Related]  

  • 42. Tocilizumab for giant cell arteritis: what is optimal?
    Kaymakci M; Warrington KJ
    Clin Exp Rheumatol; 2023 Apr; 41(4):777-779. PubMed ID: 36995336
    [No Abstract]   [Full Text] [Related]  

  • 43. [Rheumatoid polyarthritis: a new treatment].
    Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636
    [No Abstract]   [Full Text] [Related]  

  • 44. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
    Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
    Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosing and managing polymyalgia rheumatica and temporal arteritis. Urgency in giving steroids in giant cell arteritis is still not widely appreciated.
    Freeman AG
    BMJ; 1997 Aug; 315(7107):549-50. PubMed ID: 9329328
    [No Abstract]   [Full Text] [Related]  

  • 46. Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits.
    Buttgereit F; Palmowski A; Esen I; Brouwer E
    Arthritis Rheumatol; 2023 Apr; 75(4):489-492. PubMed ID: 36468520
    [No Abstract]   [Full Text] [Related]  

  • 47. Occult giant cell arteritis and steroid therapy: how urgent is urgent?
    Mitra A; Chavan R; Gunda M
    Ann Ophthalmol (Skokie); 2006; 38(4):343-5. PubMed ID: 17726223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immunosuppressive agents in Horton's disease. Which drug for which indication?].
    Roblot P
    Ann Med Interne (Paris); 1998 Nov; 149(7):441-7. PubMed ID: 9921398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A case of fatal, relapsing GCA following one year of tocilizumab.
    Ming C; Stack J
    Rheumatology (Oxford); 2020 Jul; 59(7):1777-1778. PubMed ID: 31821468
    [No Abstract]   [Full Text] [Related]  

  • 50. Steroid-responsive charles bonnet syndrome in temporal arteritis.
    Razavi M; Jones RD; Manzel K; Fattal D; Rizzo M
    J Neuropsychiatry Clin Neurosci; 2004; 16(4):505-8. PubMed ID: 15616179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis.
    Tomelleri A; Rinaldi E; Campochiaro C; Picchio M; Dagna L
    Rheumatology (Oxford); 2023 Feb; 62(2):e24-e26. PubMed ID: 35861513
    [No Abstract]   [Full Text] [Related]  

  • 52. Outcomes of giant cell arteritis patients treated with tocilizumab in a single neuro-ophthalmology practice.
    Fong JW; Sharieff JA; Patel AD
    Can J Ophthalmol; 2023 Apr; 58(2):e61-e62. PubMed ID: 36126697
    [No Abstract]   [Full Text] [Related]  

  • 53. Interleukin-6 as a therapeutic target in spondylarthritis: comment on the article by Tanaka et al.
    Wendling D
    Arthritis Care Res (Hoboken); 2010 May; 62(5):745; author reply 745-6. PubMed ID: 20191469
    [No Abstract]   [Full Text] [Related]  

  • 54. Treating giant-cell arteritis: is IL-6 the cytokine to target?
    Guillevin L; Régent A
    Lancet; 2016 May; 387(10031):1882-3. PubMed ID: 27203632
    [No Abstract]   [Full Text] [Related]  

  • 55. [Diagnostic (Classification) Criteria and Treatment Guidelines of Collagen-vascular Diseases: Hos to Use and Cautions on Applying Them for General Physicians. Topics: V. Giant Cell Arteritis].
    Amano K
    Nihon Naika Gakkai Zasshi; 2015 Oct; 104(10):2139-42. PubMed ID: 30160928
    [No Abstract]   [Full Text] [Related]  

  • 56. Reply to Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?
    Gordon LK; Sadun AA; Van Stavern G; Lee AG
    J Neuroophthalmol; 2022 Jun; 42(2):e535-e536. PubMed ID: 35594160
    [No Abstract]   [Full Text] [Related]  

  • 57. Is visual loss due to giant cell arteritis reversible?
    Calgüneri M; Cobankara V; Ozatli D; Güler G; Apraş S; Pay S; Kiraz S; Ertenli I; Oztürk MA
    Yonsei Med J; 2003 Feb; 44(1):155-8. PubMed ID: 12619191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis.
    Xenitidis T; Horger M; Zeh G; Kanz L; Henes JC
    Rheumatology (Oxford); 2013 Sep; 52(9):1729-31. PubMed ID: 23463808
    [No Abstract]   [Full Text] [Related]  

  • 59. Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al.
    Jover JA; Hernández-Garcia C; Morado IC; Vargas E; Bañares A; Fernandez-Gutierrez B
    Arthritis Rheum; 2003 Apr; 48(4):1158-9. PubMed ID: 12687561
    [No Abstract]   [Full Text] [Related]  

  • 60. New treatment strategies in large-vessel vasculitis.
    Unizony S; Stone JH; Stone JR
    Curr Opin Rheumatol; 2013 Jan; 25(1):3-9. PubMed ID: 23114585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.